|
| FDA Advisory Committee recommends US FDA approval of Brilinta (ticagrelor) for Acute Coronary Syndromes |
|
| AstraZeneca today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca’s investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS). |
|
 View full press release |
|
| This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. |
|
No comments:
Post a Comment